Clinical Trials

Study Title:
INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature Driven Analysis

For more information about the trial above please contact the study team: Medical University of South Carolina Principal Investigator, Mariam Alexander, at alexanma@musc.edu. Study Coordinator, Alec Schumpp, at schumpp@musc.edu. Trial opened at the following institutions: Medical University of South Carolina